Follow-up data are from a study being conducted in 5 sites in Colombia designed to evaluate the long-term immunogenicity , effectiveness , and safety of the qHPV vaccine in women who were vaccinated at 24 to 45 years of age ( in the original vaccine group during the base study [ n = 684 ] ) or 29 to 50 years of age ( in the original placebo group during the base study [ n = 651 ] ) .